Hyperphosphatemia drugs! Biomet's "Calcium Acetate Tablets" passed the consistency evaluation for the first time

On October 14th, the calcium acetate tablets of the Bermeth creature passed the consistent evaluation, which was the first in China.
acetate tablets are a phosphorus binding agent, mainly used to prevent and treat end-stage renal disease hyperphosphateemia.
phosphorusemia is a common complication of chronic kidney disease, and patients have difficulty draining phosphorus due to kidney failure, which leads to high phosphorusemia.
if hyperphosphateemia persists for too long, too high phosphorus in the body will cause calcium loss, so that the blood calcium in the blood is reduced, and thus manifest as hypocalcemia.
the current prevalence of chronic kidney disease in China is 10.8%, a total of 120 million people, of which about 2 million end-stage kidney disease patients.
end-stage dialysis patients with end-stage kidney disease treatment drugs are mainly Svilam, carbonate and calcium acetate.
IQVIA data show that in 2018 Svilam and carbonate sales in China of about 353 million yuan, both drugs have been approved for the first time in China.
medicine Rubik's Cube database PharmaGo shows that the domestic production and sale of calcium acetate tablets manufacturers have six, has not yet passed the consistent evaluation of enterprises.
addition to Bermeth Bio, there are five manufacturers that are applying for or applying for a consistent evaluation of the drug.
.